CAGRILINTIDE - 17 Annonces

Friday 29 August 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday 22 August 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Wednesday 20 August 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday 01 August 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday 25 July 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Saturday 19 July 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Thursday 17 July 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Friday 11 July 2025

Cagrilintide 是一种新型长效酰化胰高血糖素类似物，作为苦杏仁苷受体 （AMYR） 和降钙素 G 蛋白偶联受体 （CChemicalbookTR） 的非选择性激动剂，正在研究中。Cagrilintide 可显著降低体重并减少食物摄入量。Cagrilintide 具有用于肥胖研究的潜力。 品牌： Soarwin CAS号：1415456-99-3 EINECS编号：206-141-6 Localisation : 重庆渝北, 401000 渝北, Personne à contacter : meng meng, +18 7 23 93 07...

Wednesday 09 July 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday 04 July 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Tuesday 01 July 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Wednesday 25 June 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Wednesday 25 June 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Tuesday 24 June 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Friday 25 April 2025

Quantité : 9999 - Prix : 1,00 €

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Tuesday 22 April 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Wednesday 16 April 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...